Association of neighborhood socioeconomic disadvantage and cognitive impairment
Alzheimer's & Dementia · 2023-03 · 19 (3) · 761-770
DOI: 10.1002/alz.12702 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 06.06.2022. Verfasst von Maria Vassilaki und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Socioeconomic Factors, Dementia. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, the National Institutes of Health, NINDS NIH HHS.
Abstract (Originalsprache)
Introduction
We investigated the association of the area deprivation index (ADI) with cognitive decline, mild cognitive impairment (MCI), and dementia in older adults (≥50 years old). ADI is a neighborhood socioeconomic disadvantage measure assessed at the census block group level.
Methods
The study included 4699 participants, initially without dementia, with available ADI values for 2015 and at least one study visit in 2008 through 2018. Using logistic regression and Cox proportional hazards models with age as the time scale, we assessed the odds for MCI and the risk for dementia, respectively.
Results
In cognitively unimpaired (CU) adults at baseline, the risk for progression to dementia increased for every decile increase in the ADI state ranking (hazard ratio = 1.06, 95% confidence interval (1.01–1.11), P = .01). Higher ADI values were associated with subtly faster cognitive decline.
Discussion
In older CU adults, higher baseline neighborhood socioeconomic deprivation levels were associated with progression to dementia and slightly faster cognitive decline. Highlights The study used area deprivation index, a composite freely available neighborhood deprivation measure. Higher levels of neighborhood deprivation were associated with greater mild cognitive impairment odds. Higher neighborhood deprivation levels were associated with higher dementia risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Public Health Sciences, Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Förderung
- NIA NIH HHS
- the National Institutes of Health
- NINDS NIH HHS
Zitieren
APA
Vassilaki, M., Aakre, J. A., Castillo, A., Chamberlain, A. M., Wilson, P. M., Kremers, W. K., Mielke, M. M., Geda, Y. E., Machulda, M. M., Alhurani, R. E., Graff-Radford, J., Vemuri, P., Lowe, V. J., Jack, C. R., Knopman, D. S., & Petersen, R. C. (2023). Association of neighborhood socioeconomic disadvantage and cognitive impairment. Alzheimer's & Dementia, 19(3), 761-770. https://doi.org/10.1002/alz.12702
Vancouver
Vassilaki M, Aakre JA, Castillo A, Chamberlain AM, Wilson PM, Kremers WK, et al. Association of neighborhood socioeconomic disadvantage and cognitive impairment. Alzheimer's & Dementia. 2023;19(3):761-770. doi:10.1002/alz.12702
BibTeX
@article{Vassilaki2023,
author = {Vassilaki, Maria and Aakre, Jeremiah A and Castillo, Anna and Chamberlain, Alanna M and Wilson, Patrick M and Kremers, Walter K and Mielke, Michelle M and Geda, Yonas E and Machulda, Mary M and Alhurani, Rabe E and Graff-Radford, Jonathan and Vemuri, Prashanthi and Lowe, Val J and Jack, Clifford R and Knopman, David S and Petersen, Ronald C},
title = {Association of neighborhood socioeconomic disadvantage and cognitive impairment},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {3},
pages = {761--770},
doi = {10.1002/alz.12702}
}
EUVIMED